Harvia Oyj
Harvia Plc: Managers' transactions - Anssi Pelkonen
Harvia Plc: Managers' transactions - Anssi Pelkonen
HARVIA PLC STOCK EXCHANGE RELEASE 31 MARCH 2025 AT 10.00 A.M. EEST
Harvia Plc - Managers' transactions
____________________________________________
Person subject to the notification requirement
Name: Pelkonen, Anssi
Position: Other senior manager
Issuer: Harvia Plc
LEI: 7437002ULTBOWQQOXL69
Notification type: INITIAL NOTIFICATION
Reference number: 7437002ULTBOWQQOXL69_20250328110126_11
____________________________________________
Transaction date: 2025-03-27
Venue not applicable
Instrument type: SHARE
ISIN: FI4000306873
Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE
Transaction details
(1): Volume: 912 Unit price: 0.00 EUR
Aggregated transactions
(1): Volume: 912 Volume weighted average price: 0.00 EUR
Additional information:
Ari Vesterinen, CFO
tel. +358 40 5050 440
ari.vesterinen@harvia.com
Harvia is one of the leading companies operating in the sauna market globally, as measured by revenue. Harvia’s brands and product portfolio are well known in the market, and the company’s comprehensive product portfolio strives to meet the needs of the international sauna market of both private and professional customers.
Harvia’s revenue totaled EUR 175.2 million in 2024. Harvia Group employs approximately 700 professionals in Finland, United States, Germany, Romania, China and Hong Kong, Austria, Italy, Estonia, and Sweden. The company is headquartered in Muurame, Finland, adjacent to its largest sauna and sauna component manufacturing facility.
Read more: https://harviagroup.com
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Tenaris SA2.4.2025 00:05:53 CEST | Press release
Tenaris Files 2024 Annual Report / Annual Report on Form 20-F, and Convenes the Annual General Meeting of Shareholders and an Extraordinary General Meeting of Shareholders
INVENTIVA1.4.2025 23:00:00 CEST | Press release
Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis
Respilean1.4.2025 22:30:10 CEST | Press release
Respilean Review (BREAKING NEWS): Why Thousands Are Calling It the Natural Lung Breakthrough of 2025
nCino, Inc.1.4.2025 22:06:00 CEST | Press release
nCino Reports Fourth Quarter and Fiscal Year 2025 Financial Results
nCino, Inc.1.4.2025 22:05:00 CEST | Press release
nCino Announces Stock Repurchase Program
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom